Detalhe da pesquisa
1.
SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms.
Cell
; 184(10): 2605-2617.e18, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33831372
2.
Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation.
Nature
; 615(7950): 143-150, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630998
3.
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
PLoS Pathog
; 20(4): e1011680, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635853
4.
Characterization of treatment resistance and viral kinetics in the setting of single- versus dual-active monoclonal antibodies against SARS-CoV-2.
J Infect Dis
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38716969
5.
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
Ann Intern Med
; 176(3): 348-354, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36802755
6.
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
Ann Intern Med
; 176(12): 1577-1585, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37956428
7.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Ann Intern Med
; 176(5): 658-666, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068272
8.
Variant-Specific Viral Kinetics in Acute COVID-19.
J Infect Dis
; 228(Suppl 2): S136-S143, 2023 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37650233
9.
Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).
Clin Infect Dis
; 76(3): e526-e529, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35737946
10.
Genome-wide association analysis of COVID-19 mortality risk in SARS-CoV-2 genomes identifies mutation in the SARS-CoV-2 spike protein that colocalizes with P.1 of the Brazilian strain.
Genet Epidemiol
; 45(7): 685-693, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159627
11.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection.
Clin Infect Dis
; 74(2): 237-245, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906227
12.
Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination.
Clin Infect Dis
; 74(7): 1275-1278, 2022 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363462
13.
Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) Survival.
Clin Infect Dis
; 74(6): 1081-1084, 2022 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245255
14.
Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children.
J Infect Dis
; 224(11): 1821-1829, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34647601
15.
Impact of pre-existing drug resistance on risk of virological failure in South Africa.
J Antimicrob Chemother
; 76(6): 1558-1563, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33693678
16.
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection.
N Engl J Med
; 387(3): 275-277, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767428
17.
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.
N Engl J Med
; 383(23): 2291-2293, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176080
18.
Uncovering hidden sources of SARS-CoV-2 viral evolution: A call to action.
Transpl Infect Dis
; 24(6): e13910, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35899935
19.
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency.
Sci Transl Med
; 16(731): eadk1599, 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266109
20.
S:D614G and S:H655Y are gateway mutations that act epistatically to promote SARS-CoV-2 variant fitness.
bioRxiv
; 2023 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37034621